Blood Vessels Recovered With Organs and Intended for Use in Organ Transplantation; Withdrawal, 54198 [06-7644]
Download as PDF
<![CDATA[
54198
Federal Register / Vol. 71, No. 178 / Thursday, September 14, 2006 / Rules and Regulations
withholding any portion of the
information and show why the
information is a trade secret or
commercial or financial information
that is privileged or confidential.
Because CBP wished to continue its
practice of not requiring business
submitters of commercial information to
designate such information as protected
from disclosure, it published an interim
rule in the Federal Register (68 FR
47453) on August 11, 2003, as CBP
Decision 03–02 that amended Part 103
of the CBP regulations by adding a new
§ 103.35 to subpart C. New § 103.35
adopted Treasury’s established
disclosure procedure that had been
followed by Customs since 1987 to
assure the trading community that the
transfer of Customs from Treasury to
DHS would not affect the treatment of
commercial information that business
submitters provide to CBP.
The comment period for the interim
regulations closed on October 10, 2003.
No comments were received from the
public in response to the interim rule,
and CBP is now adopting the interim
rule as a final rule without change.
This final rule is being issued in
accordance with 19 CFR 0.2(a)
pertaining to the authority of the
Secretary of the Department of
Homeland Security, or his or her
designee, to issue Customs regulations
that are not related to customs revenue
functions.
Regulatory Flexibility Act and
Executive Order 12866
As discussed above, these regulations
were published as an interim rule on
August 11, 2003. Because no notice of
proposed rulemaking was required, the
provisions of the Regulatory Flexibility
Act (5 U.S.C. 601 et seq.) do not apply.
Further, this document does not meet
the criteria for a ‘‘significant regulatory
action’’ as specified in Executive Order
12866.
List of Subjects in 19 CFR Part 103
Administrative practice and
procedure, Confidential commercial
information, Freedom of Information,
Reporting and recordkeeping
requirements.
Amendments to the Regulations
For the reasons set forth above, the
interim rule amending part 103 of title
19 of the Code of Federal Regulations
(19 CFR part 103), which was published
in the Federal Register at 68 FR 47453
on August 11, 2003, is adopted as a final
rule without change.
sroberts on PROD1PC70 with RULES
VerDate Aug<31>2005
20:51 Sep 13, 2006
Jkt 208001
Systems Bureau, Health Resources
and Services Administration, 5600
Fishers Lane, room 12C–06,
Rockville, MD 20857, 301–443–
7577.
HRSA and
FDA published a direct final rule in the
Federal Register of May 12, 2006 (71 FR
27606), to amend the regulations to
consider as part of an organ those blood
vessels recovered with the organ that are
intended for use in organ
transplantation (HRSA regulation); and
to exclude such blood vessels from the
definition of human cells, tissues, and
cellular and tissue-based products (FDA
regulation).
HRSA and FDA received significant
adverse comment in response to the
direct final rule. Therefore, the direct
final rule is being withdrawn. HRSA
and FDA intend to finalize the proposed
rule after considering comments.
Authority: Therefore, under the
Public Health Service Act and under
authority delegated to the Commissioner
of Food and Drugs and to the
Administrator, Health Resources and
Services Administration, the direct final
rule published on May 12, 2006 (71 FR
27606), is withdrawn.
SUPPLEMENTARY INFORMATION:
BILLING CODE 9111–14–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Part 1271
[Docket No. 2006N–0051]
Health Resources and Services
Administration
42 CFR Part 121
Blood Vessels Recovered With Organs
and Intended for Use in Organ
Transplantation; Withdrawal
AGENCIES: Food and Drug
Administration, Health Resources and
Services Administration, HHS.
ACTION: Direct final rule; withdrawal.
SUMMARY: The Health Resources and
Services Administration (HRSA) and the
Food and Drug Administration (FDA)
published in the Federal Register of
May 12, 2006 (71 FR 27606), a direct
final rule to amend the regulations to
consider as part of an organ those blood
vessels recovered with the organ that are
intended for use in organ
transplantation; and to exclude such
blood vessels from the definition of
human cells, tissues, and cellular and
tissue-based products. The comment
period closed July 26, 2006. HRSA and
FDA are withdrawing the direct final
rule because FDA received significant
adverse comment. The agencies will
consider the comments received under
our usual procedures for notice and
comment in connection with the notice
of proposed rulemaking that was
published as a companion to the direct
final rule (71 FR 27649).
DATES: The direct final rule published
on May 12, 2006 (71 FR 27606), is
withdrawn effective September 14,
2006.
SUMMARY: This final rule transfers
responsibility for final agency decisions
in connection with Post OfficeTM box
termination, caller service termination,
and denial of service appeals from the
Judicial Officer Department to the vice
president and Consumer Advocate.
DATES: Effective Date: September 1,
2006.
FOR FURTHER INFORMATION CONTACT:
Signing Authority
I
Dated: September 8, 2006.
Deborah J. Spero,
Acting Commissioner, Customs and Border
Protection.
[FR Doc. E6–15225 Filed 9–13–06; 8:45 am]
FOR FURTHER INFORMATION CONTACT:
For information regarding FDA’s rule:
Pamela Pope, Center for Biologics
Evaluation and Research (HFM–17),
Food and Drug Administration,
1401 Rockville Pike, suite 200N,
Rockville, MD 20852–1448, 301–
827–6210.
For information regarding HRSA’s
rule: Jim Burdick, Division of
Transplantation, Healthcare
PO 00000
Frm 00004
Fmt 4700
Sfmt 4700
Dated: September 6, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 06–7644 Filed 9–13–06; 8:45 am]
BILLING CODE 4160–01–S
POSTAL SERVICE
39 CFR Parts 111 and 958
Post Office Box and Caller Service
Postal Service.
Final rule.
AGENCY:
ACTION:
Mr.
Anthony F. Alverno, Chief Counsel,
Customer Programs, 202–268–2997.
SUPPLEMENTARY INFORMATION: At
present, if a postmaster denies a
customer’s application for Post Office
box or caller service or terminates a
customer’s Post Office box or caller
service, the postmaster must issue a
written letter explaining his or her
decision and include a copy of the
E:\FR\FM\14SER1.SGM
14SER1
]]>Agencies
[Federal Register Volume 71, Number 178 (Thursday, September 14, 2006)]
[Rules and Regulations]
[Page 54198]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-7644]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 1271
[Docket No. 2006N-0051]
Health Resources and Services Administration
42 CFR Part 121
Blood Vessels Recovered With Organs and Intended for Use in Organ
Transplantation; Withdrawal
AGENCIES: Food and Drug Administration, Health Resources and Services
Administration, HHS.
ACTION: Direct final rule; withdrawal.
-----------------------------------------------------------------------
SUMMARY: The Health Resources and Services Administration (HRSA) and
the Food and Drug Administration (FDA) published in the Federal
Register of May 12, 2006 (71 FR 27606), a direct final rule to amend
the regulations to consider as part of an organ those blood vessels
recovered with the organ that are intended for use in organ
transplantation; and to exclude such blood vessels from the definition
of human cells, tissues, and cellular and tissue-based products. The
comment period closed July 26, 2006. HRSA and FDA are withdrawing the
direct final rule because FDA received significant adverse comment. The
agencies will consider the comments received under our usual procedures
for notice and comment in connection with the notice of proposed
rulemaking that was published as a companion to the direct final rule
(71 FR 27649).
DATES: The direct final rule published on May 12, 2006 (71 FR 27606),
is withdrawn effective September 14, 2006.
FOR FURTHER INFORMATION CONTACT:
For information regarding FDA's rule: Pamela Pope, Center for
Biologics Evaluation and Research (HFM-17), Food and Drug
Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852-
1448, 301-827-6210.
For information regarding HRSA's rule: Jim Burdick, Division of
Transplantation, Healthcare Systems Bureau, Health Resources and
Services Administration, 5600 Fishers Lane, room 12C-06, Rockville, MD
20857, 301-443-7577.
SUPPLEMENTARY INFORMATION: HRSA and FDA published a direct final rule
in the Federal Register of May 12, 2006 (71 FR 27606), to amend the
regulations to consider as part of an organ those blood vessels
recovered with the organ that are intended for use in organ
transplantation (HRSA regulation); and to exclude such blood vessels
from the definition of human cells, tissues, and cellular and tissue-
based products (FDA regulation).
HRSA and FDA received significant adverse comment in response to
the direct final rule. Therefore, the direct final rule is being
withdrawn. HRSA and FDA intend to finalize the proposed rule after
considering comments.
Authority: Therefore, under the Public Health Service Act and under
authority delegated to the Commissioner of Food and Drugs and to the
Administrator, Health Resources and Services Administration, the direct
final rule published on May 12, 2006 (71 FR 27606), is withdrawn.
Dated: September 6, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 06-7644 Filed 9-13-06; 8:45 am]
BILLING CODE 4160-01-S
